Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide vs Bortezomib in Melphalan Refractory Myeloma
NCT00602511Phase 3Completed
- Sponsor
- Nordic Myeloma Study Group
- Start
- Oct 2007
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by Nordic Myeloma Study Group. Primary endpoint: Progression free survival. Started Oct 2007; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00602511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602511.